Pickering Emulsions for mRNA Cancer Vaccine Delivery: Mechanistic Insights

Study Background and Research Question

Therapeutic cancer vaccines are a foundational pillar of contemporary immunotherapy, aiming to stimulate the immune system to recognize and eradicate malignant cells, especially in challenging tumor types. A persistent obstacle in vaccine design is to achieve efficient delivery and presentation of antigens while ensuring biosafety and robust immune activation. In the wake of mRNA vaccine successes for infectious diseases, such as COVID-19, attention has turned to mRNA-based cancer vaccines. However, challenges remain: mRNA is inherently unstable and can be rapidly degraded, and commonly used lipid nanoparticle (LNP) systems originally optimized for liver targeting may not maximize dendritic cell (DC) activation or tumor-site localization. The question addressed by Yufei Xia's doctoral thesis (Yufei Xia Ph.D Thesis, 2024) is whether multiple Pickering emulsion (mPE) systems—specifically, water-in-oil-in-water (W/O/W) emulsions stabilized by biocompatible particles—can serve as advanced delivery platforms for both protein and mRNA cancer vaccines, with improved antigen delivery, immune activation, and tumor suppression.

Key Innovation from the Reference Study

The thesis presents several interlinked innovations. Foremost, it develops a multi-level structured Pickering emulsion platform capable of encapsulating protein antigens or mRNA within an inner aqueous phase, shielded by an oil layer and stabilized by particulate interfaces. This structure offers dual benefits: physical protection of sensitive cargo (such as mRNA) from enzymatic degradation, and enhanced interaction with key immune cells. Importantly, the work systematically compares Pickering emulsions stabilized by distinct particles—calcium phosphate (CaP), silicon dioxide (SiO₂), and aluminum (Alum)—elucidating how surface charge and particle chemistry modulate antigen release, dendritic cell activation, and in vivo immunogenicity. The CaP-PME formulation, in particular, demonstrates superior mRNA release and DC activation, setting a new benchmark for mRNA vaccine delivery platforms.

Methods and Experimental Design Insights

The experimental approach integrates formulation science, immunological assays, and in vivo tumor models. Key steps include:

• Preparation of W/O/W multiple Pickering emulsions, where protein or mRNA is loaded into the inner aqueous phase, the oil phase acts as a barrier, and the outer aqueous phase contains the stabilizing particles.
• Use of CaP, SiO₂, and Alum nanoparticles to stabilize the emulsion interfaces, allowing a direct comparison of their immunological effects.
• Encapsulation efficiency, mRNA stability, and transfection capability are assessed both in vitro (e.g., using bone marrow–derived dendritic cells, BMDCs) and in vivo (murine tumor models).
• Immunogenicity is quantified by measuring antigen-specific IgG subclasses, dendritic cell activation markers (such as CD40), and cytokine secretion (e.g., IFN-γ from T cells).
• Tumor suppression is evaluated in established mouse models, enabling direct comparison of the mPE vaccines against conventional adjuvants and LNP-based mRNA vaccines.

Protocol Parameters

• mRNA encapsulation: Optimize the inner aqueous phase for maximal mRNA loading; pH and ionic strength adjustments may enhance encapsulation.
• Particle selection: Choose CaP nanoparticles for enhanced dendritic cell activation and cytoplasmic mRNA delivery.
• Emulsion preparation: Maintain low shear mixing to preserve mRNA integrity and ensure stable W/O/W droplet formation.
• In vivo administration: For anti-tumor studies, inject emulsions subcutaneously near lymphatic drainage sites to maximize immune cell access.

Core Findings and Why They Matter

Three principal findings emerge from the thesis:

1. Enhanced Antigen Delivery and Immune Activation: mPEs facilitate high loading and stable delivery of protein antigens, resulting in elevated antigen-specific IgG1 and IgG2a responses compared to traditional aluminum adjuvants. CaP-stabilized emulsions most effectively activate dendritic cells, as evidenced by increased CD40 expression and IFN-γ-secreting T cells.
2. mRNA Vaccine Delivery with Cytoplasmic Release: Unlike Alum-PMEs (which retain mRNA at the emulsion surface and block transfection), negatively charged CaP- and SiO₂-PMEs enable efficient mRNA release into the cytoplasm, resulting in robust protein expression and DC stimulation. The oil phase acts as a protective shield, reducing mRNA degradation—a major limitation of standard delivery approaches.
3. Tumor-Suppressive Efficacy and Safety: In mouse tumor models, CaP-PME–delivered mRNA vaccines outperform LNP-based systems in terms of dendritic cell targeting, immune activation, and tumor growth inhibition. Furthermore, Pickering emulsions avoid liver accumulation, confining protein expression to the injection site and improving biosafety profiles.

These results indicate that Pickering emulsions can serve as dual-function platforms for both antigen protection and immune potentiation, specifically addressing the challenges of mRNA delivery and innate immune activation suppression in the context of cancer immunotherapy.

Comparison with Existing Internal Articles

Several internal resources provide complementary perspectives on the design and application of advanced mRNA delivery tools. For instance, the article "Translating Mechanistic Innovation into Impact" discusses the integration of Cap 1 capping and 5-moUTP nucleotide modification to enhance mRNA translation and minimize immune activation. While the reference thesis focuses on particulate- and emulsion-based delivery, the internal article emphasizes the biochemical optimization of mRNA itself, such as the use of EZ Cap™ Firefly Luciferase mRNA (5-moUTP), which incorporates 5-methoxyuridine for stability and immune evasion.

Another resource, "Mechanism, Evidence, and Workflows", details how chemically modified luciferase mRNA supports high-sensitivity bioluminescent reporter gene assays. The intersection is clear: optimizing both the delivery vehicle (e.g., Pickering emulsions) and the mRNA payload (e.g., Cap 1 capping and 5-moUTP modification) is critical for reliable mRNA delivery and translation efficiency assay outcomes. The present thesis adds new evidence that particulate emulsion systems, particularly those stabilized by CaP, are well suited for DC targeting and tumor-specific immune responses, providing a mechanistic rationale that complements these internal workflow recommendations.

Limitations and Transferability

Despite the promising results, several limitations should be considered. First, the thesis' findings are primarily based on murine models; thus, the translatability to human immune systems and clinical efficacy requires further validation. Second, while CaP-PMEs demonstrate superior delivery and immune activation, formulation complexity and scalability for GMP manufacturing remain to be addressed. Third, the universal applicability of these emulsions to other mRNA cargos or cancer types will depend on the compatibility of antigen sequence, emulsion composition, and injection route. Notably, the potential for poly(A) tail mRNA stability and innate immune activation suppression—key strengths of 5-moUTP modified mRNA—may be further enhanced when combined with optimized particulate delivery, but this synergy awaits direct experimental confirmation.

Research Support Resources

For researchers seeking to replicate or extend these findings, in vitro transcribed capped mRNA with chemical modifications is essential for robust gene expression studies and mRNA delivery experiments. Products such as EZ Cap™ Firefly Luciferase mRNA (5-moUTP) (SKU R1013) from APExBIO offer a convenient option, incorporating 5-moUTP for reduced immunogenicity and an optimized poly(A) tail for transcript stability. When combined with advanced delivery systems like Pickering emulsions, these mRNAs facilitate reliable translation efficiency assays, bioluminescent reporter gene studies, and mechanistic investigations into DC-targeted vaccine delivery. For detailed mechanistic and workflow strategy, internal resources such as "Reliable Bioluminescence: EZ Cap™ Firefly Luciferase mRNA (5-moUTP)" provide additional protocol insights and troubleshooting guidance.